Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Aritro Nath · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2024 · $88,666 — Abstract Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative, breast cancer patients. However, the value of this combination in potentially curable earlier stage patients is variable. Our prelimina…
JAMES Bryant HURLEY · UNIVERSITY OF WASHINGTON · 2024 · $441,250 — Project Summary/Abstract Metabolic relationships between retina and RPE are essential for retina function and survival. Biochemical comparisons of explanted retina to RPE/choroid have revealed striking metabolic differences. Retinas consume glucose rapidly and convert most of it to lactate. Cultured…
David G. Schatz · YALE UNIVERSITY · 2024 · $563,811 — Despite four decades of study, major gaps remain in our understanding of key molecular and cellular processes that orchestrate the action of the RAG1/RAG2 endonuclease during antigen receptor (AgR) gene assembly by V(D)J recombination. V(D)J recombination occurs in focal regions of RAG binding in Ag…
Ravi Bhasker Patel · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $580,985 — Project Summary & Abstract Adoptive T cell therapies (ACT) including chimeric antigen receptor (CAR) T cells are novel immunotherapies with unparalleled successes, especially in patients with leukemia. However, they have limited efficacy in solid tumors. One barrier to success is the ability of ACT …
Zhenyu Yue · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $453,906 — Our goal is to elucidate molecular mechanism for neuroprotective autophagy in Huntington's disease (HD) and determine therapeutic potential for selective autophagy in treating the disease. HD is caused by an aberrant expansion of CAG repeat (polyQ) in the HTT gene, which leads to a toxic gain-of-fun…
Matthew Ryan Brier · WASHINGTON UNIVERSITY · 2024 · $232,918 — ABSTRACT Multiple sclerosis (MS) is an immune-mediated, demyelinating, and degenerative disease of the central nervous system and is a leading cause of disability in young people. Most patients begin with a relapsing- remitting (RRMS) course. Clinical relapse and new white matter lesion formation is…
Or Shemesh · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $198,750 — Abstract Glia are supportive cells in the human brain, comprising microglia, oligodendrocytes, astrocytes, and ependymal cells. Glia are deeply involved in diseases of the nervous system such as Alzheimer’s (AD), autism, pain, affective disorders, and cancers. Different glial cell types play differe…
Jason Becker · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $744,195 — Project Summary: Multiple acquired and genetic conditions can lead to pathological left ventricular hypertrophy (LVH). It has been recognized for over 50 years that pathological LVH is associated with increased mortality in the human population, and it is strongly associated with both heart failure …
Vinitha Jacob · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $159,300 — PROJECT SUMMARY/ABSTRACT Sepsis is a common and deadly disease and treatment options are limited to antibiotics and supportive care. Endotoxemia is a key feature of sepsis pathogenesis and can also contribute to numerous other inflammatory disorders. Growing antibiotic resistance and an aging popul…
Varghese John · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $639,946 — PROJECT SUMMARY/ABSTRACT Our recent discovery of orally brain permeable small molecules that mimic the bioactivity of Humanin (HN) peptide to enhance and normalize neuronal phospho-Akt (p-Akt) levels provides a unique opportunity for evaluating this new approach in Alzheimer's disease (AD). In this …
JEFFERY W KELLY · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $898,395 — A common molecular phenotype exists for most neurodegenerative diseases, including protein and/or protein- RNA aggregation, lipid level perturbations, mitochondrial dysfunction, lysosomal dysfunction, and neuro- inflammation. The literature provides evidence that this pathogenic signature of Alzheim…
Andrea Pappalardo Wlochowicz · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $178,783 — Project Summary/Abstract: Candidate: This K23 award will provide an opportunity for Dr. Pappalardo to realize her goal of becoming an independently funded clinician scientist leading multi-level community-engaged implementation science interventions that dismantle persistent asthma health disparitie…
FATEMEH G HAGHIGHI · JAMES J PETERS VA MEDICAL CENTER · 2024 — We propose a set of studies focused on the association of suicide with neuroinflammation and compromise of the blood-brain barrier, with the goal of identifying a pattern of quantifiable abnormalities that could serve as a biomarker for imminent suicidal risk in our Veterans. Autopsy studies are uni…
Timothy Brandon Ware · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $76,756 — Project Summary/Abstract The goal of this proposal is to understand how transmembrane protein 164 (TMEM164) attenuates polyunsaturated fatty acid (PUFA) metabolism and ferroptotic signaling. Ferroptosis is a novel iron-dependent form of cell death implicated in a broad range of human diseases, inclu…
Neil C Chi · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $620,622 — Project Summary Congenital Heart Disease is the most common congenital anomaly in newborn babies, accounting for one third of all major congenital anomalies. Despite recent congenital heart disease genetic studies highlighting the critical role of cardiac transcriptional and chromatin regulators dur…
Erik Knudsen · ROSWELL PARK CANCER INSTITUTE CORP · 2024 · $479,955 — Pancreatic ductal adenocarcinoma (PDAC) represents a therapy recalcitrant disease with 5-year survival rate of approximately 10%. Multiple failed clinical trials reinforce the need for new approaches to treatment that employ rationally developed therapies targeting key genetic features of PDAC tumor…
Zita Oravecz · PENNSYLVANIA STATE UNIVERSITY, THE · 2024 · $778,936 — Project Summary Sensitive and accurate measurement of change in cognitive performance is necessary for the detection of subtle cognitive decline in the preclinical phase of Alzheimer’s disease and related dementias (ADRD). It is also required to evaluate outcomes of early interventions aimed at miti…
Sudip Mondal · VIVOVERSE, LLC · 2024 · $287,021 — Neurodevelopmental disorders such as ADHD, autism, and learning disabilities are rising globally. In the US, 1 in 6 children suffer from some form of developmental disability. One potentially important factor in their increase is exposure to chemicals of unknown toxicity in the environment. While th…
Aivi Thanh Nguyen · MAYO CLINIC ROCHESTER · 2024 · $155,520 — PROJECT DESCRIPTION/ABSTRACT This NIH K08 proposal describes a five-year career development plan for Dr. Aivi T. Nguyen to obtain the necessary research and professional skills and serve as transition to become a successful, independently funded physician-scientist. Dr. Nguyen completed her clinical…
Donald R Sullivan · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $753,600 — PROJECT SUMMARY The over 6 million Americans with Alzheimer’s Disease and Related Dementias (ADRD) are particularly vulnerable to burdensome, low-quality, and costly care at the end of life. Research has highlighted the need to increase the use of palliative care in patients with ADRD as they have n…